MedTrace Logo

MiACLR: Michigan Initiative for Anterior Cruciate Ligament Rehabilitation

NCT03626857 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 135

Last updated 2026-01-02

Study results available
· View outcomes & findings →

Summary

This clinical trial evaluates interventions to maximize muscle function and improve cartilage health following anterior cruciate ligament reconstruction. Improving muscle function may improve patient outcomes, improve joint mechanics, and potentially serve as a prevention approach for post-traumatic knee osteoarthritis. Knee osteoarthritis (OA) is a disabling disease that carries a substantial burden to society and to the individual affected.

Conditions

  • Anterior Cruciate Ligament Injury

Interventions

DEVICE

Neuromuscular Electrical Stimulation (NMES)

The electrical stimulator will deliver a 2500 Hz alternating current, modulated at 75 bursts/s, with a ramp-up time of 2-seconds, followed by a 50-second rest period. Stimulus intensity set to generate a maximum voluntary isometric contraction (MVIC) of at least 40\& of the contralateral MVIC.

OTHER

Eccentric Exercise (ECC)

4 sets of 10 repetitions of an eccentric leg press exercise performed at 70-90% of the 1 repetition maximum

DEVICE

Neuromuscular Electrical Stimulation (NMES) placebo

The electrical stimulator will deliver a 2500 Hz alternating current, modulated at 75 bursts/s, with a ramp-up time of 2-seconds, followed by a 50-second rest period. Stimulus intensity set to generate a maximum voluntary isometric contraction (MVIC) of 10-20% of the contralateral MVIC.

OTHER

Eccentric Exercise (ECC) placebo

4 sets of 10 repetitions of an eccentric leg press exercise performed at 10-20% of the 1 repetition maximum

Sponsors & Collaborators

  • Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

    collaborator NIH

  • University of Connecticut

    collaborator OTHER

  • University of Delaware

    collaborator OTHER

  • University of North Carolina, Chapel Hill

    collaborator OTHER

  • University of Michigan

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
14 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-02-22
Primary Completion
2025-01-09
Completion
2025-01-09

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03626857 on ClinicalTrials.gov